In a groundbreaking initiative, the United States military is preparing to implement MDMA-assisted therapy for active-duty soldiers grappling with post-traumatic stress disorder (PTSD). Funded by the Department of Defense, this pioneering research aims to provide a therapeutic avenue for 186 service members, with hopes that it will enhance their resilience and mental health, ultimately allowing them to serve more effectively and transition out of military life more successfully.
A New Approach to PTSD Treatment
The forthcoming studies, which are set to commence next year, signify a potential shift in how the military addresses the psychological aftermath of combat. Deputy Under Secretary of War for Personnel and Readiness, Sean O’Keefe, is closely monitoring these developments. The initiative follows a directive included in the National Defence Authorization Act, signed by former President Joe Biden in December 2023, which emphasised the necessity for innovative treatment options for service personnel.
Rick Doblin, the founding president of the Multidisciplinary Association for Psychedelic Studies (MAPS), expressed optimism regarding the therapy’s potential. “Helping people process trauma, whoever they are, is probably better than not,” he stated, underscoring the commitment to supporting those who serve.
The initiative will involve training a cadre of therapists from both the Department of Defense and the Department of Veterans Affairs, who will begin their education in psychedelic-assisted therapy shortly. This is a crucial step towards enabling the safe and effective administration of MDMA therapy to soldiers in need.
Legislative Support and Personal Testimonies
The impetus for this research comes partly from the advocacy of veteran Congressman Morgan Luttrell, who has championed the cause of psychedelic therapy for military personnel. Luttrell highlighted the urgency of the situation, stating, “Our men and women in uniform deserve every tool available to heal and stay in the fight.” His personal experiences with psychedelic therapy lend weight to his advocacy, as he emphasised the importance of providing service members with all possible resources to combat PTSD.
On 18 April, Luttrell stood alongside former President Donald Trump as he signed an executive order aimed at expediting research into psychedelics and improving access to these treatments, particularly for veterans. “The suicide epidemic among veterans is a national tragedy,” Trump remarked, highlighting the critical need for effective interventions in mental health care for those who have served.
Historical Context and Evolving Treatment Paradigms
Historically, the treatment of PTSD within the military has evolved significantly. During World War II, soldiers were administered barbiturates that induced deep sleep, allowing many to return to combat without addressing the underlying trauma. However, it became evident that such treatments did not provide lasting relief.
In contrast, MDMA and other psychedelics, such as psilocybin, show promise in effectively treating mental health challenges. Yet, experts caution against the potential consequences of returning soldiers to combat after undergoing therapy. Dennis McKenna, an ethnobotanist, voiced concerns regarding the ethical implications of using such treatments to prepare soldiers for the battlefield, suggesting that it could lead to a cycle of trauma and recovery that ultimately exploits the individual’s mental health.
The Future of MDMA Therapy in Military Settings
The MDMA studies will mark the first official exploration of psychedelics’ effects on military personnel. Current research plans include two randomised placebo-controlled trials, set to begin recruiting volunteers later this year. Each study will involve administering MDMA to participants over a period of ten months, allowing for a comprehensive evaluation of its effectiveness.
Experts like Rachel Yehuda, director of the Parsons Research Center for Psychedelic Healing, have also raised pertinent questions about the long-term implications of such treatments. Emotional training, potentially integrated into basic training, could equip soldiers with tools to mitigate future trauma, reducing the likelihood of PTSD developing post-deployment.
In parallel, similar therapies are being explored internationally. In Ukraine, for example, MAPS has begun training therapists to deliver MDMA-assisted therapy to military personnel amid rising concerns over untreated PTSD in the country’s armed forces.
Why it Matters
The introduction of MDMA-assisted therapy for active-duty soldiers represents a significant evolution in the military’s approach to mental health care. As the United States grapples with the enduring consequences of veteran suicides and combat-related trauma, this initiative could pave the way for a more compassionate and effective model of psychological support. By prioritising the mental well-being of those who serve, the military may not only enhance combat readiness but also foster a culture of care that acknowledges the profound psychological toll of warfare.
